Replies to post #817670 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

No, he doesn't realize that or even care to understand it. False hope and hype.
The 2 vaccines are not the same, nor will NWBO be involved in any advancements or commercialization of ATL DC if it progresses to that point. NWBO had their shot with DCVax and failed, IMO. UCLA could in no way be happy with LP , her hobby company, and team of outside consultants. UCLA has their own in-house manufacturing, so they don't need Advent either.
The most likely outcome from the November CHM meeting was a concurrence with MHRA that DCVax was precluded from approval. If the advisement was positive, an approval would have been issued by MHRA shortly thereafter in December - the more likely scenario is that LP is using her appeal process, which could take up to 6 months more of delay (around end of April) for the inevitable rejection. This is assuming that the CHM was referring to DCVax when they said "a drug for brain cancer" back in November.
These are my opinions, good luck to all.

Manufacturing and Formulation Process — DCVax-L is a proprietary product developed and commercialized by Northwest Biotherapeutics (NWBO). It uses a specific patented process for dendritic cell maturation and activation. ATL-DC refers more generally to autologous tumor lysate-pulsed DC vaccines used in various academic trials (e.g., at UCLA or other institutions), which may employ slightly different protocols for cell maturation, activation (e.g., using specific cytokines or aDC1 protocols), dosing schedules, or refinements over time. Some sources note that UCLA's ATL-DC versions have evolved separately with refinements, and patents indicate they are not identical duplicates.
Specific Additives or Adjuvants — In some ATL-DC trials (e.g., UCLA Phase II studies), the vaccine has been combined with TLR agonists (like poly-ICLC or resiquimod) as adjuvants to enhance immune polarization (e.g., boosting interferon responses). DCVax-L trials (including the large Phase III) have primarily tested it without such mandatory adjuvants, though combinations are explored separately.